Introduction
The search for new and effective pharmacologic agents has never been easy. Intuition, deduction and serendipity have guided drug design and discovery; clinical testing and postmarket surveillance further impact the ultimate market acceptance of new therapeutics. In spite of major advances in human genomics and pharmacology, productivity may be declining, with only 17 new drugs approved by the FDA in 2007, mirroring a trend line of lower and lower output of approved drugs [1] . The potential causes of this discovery 'jeopardy' include changes in the size, management and corporate cultures of large pharmaceutical companies, increased reliance on blockbuster compounds, and shifting emphasis by regulatory agencies [2, 3] . Indeed, there have been calls for radical changes in the drug approval process, particularly for the development of drugs that fulfill unmet medical needs and have high commercial risks [4] . The low R&D productivity, expiring patents of current drugs and limited pipelines have created a significant wave of acquisitions of small biotechnology companies by larger pharmaceutical companies, suggesting that some of the more creative approaches lie outside the domain of larger R&D organizations, further implying that smaller, technology-oriented companies can more readily adapt novel methods for drug discovery [5] . This review outlines some of the more Defining and contrasting drug-like molecules, druggable targets, and disease-related pathways has been somewhat difficult. Historical approaches for predicting 'druglikeness' of new chemical entities (NCEs) have often relied on Lipinski's 'Rule of Five' and related measures, which state that an NCE should have a molecular weight less than 500, a partition coefficient log P less than 5, no more than 5 H-bond donors or more than 10 H-bond acceptors [6] . Small molecule chemical libraries are often coupled with high-throughput screening of defined protein targets to profile 'chemical space'; this approach has led to the identification of lead compounds that can be subsequently optimized for target-specific effects [7] . The NIH has developed a molecular library initiative to expand the availability and diversity of small molecules available for screening in the research and academic community, with the goal of developing molecules that can interact with thousands of new targets predicted by proteomics and genomics [8] . Computational methods have been used extensively to both refine the NCEs and the target -this approach can be used to prioritize specific proteins or protein fragment targets for further alignment with putative drug candidates [9] . However, ab initio computational efforts must rely on a significant amount of a priori knowledge of the drug target and its relationship to the disease.
Central to this argument is that only a portion of gene targets have been targeted by currently available agents and approaches, and that application of functional genomics, proteomics and bioinformatics can expand these targets, the so-called 'druggable genome' [10] . Current best estimates are that of the 25,000 or so human genes, only 400-1,000 genes are currently drug targets [11] . The druggable genome has been estimated at 3,000 genes, with another 4,000 genes involved in disease modification processes [12] . The genomes of pathogenic organisms represent an additional set of therapeutic targets ( fig. 1 ). The notion is that the intersection of diseasemodifying genes with current drug targets represents the current druggable genome, but this assumes that disease and drug target genes are overlapping, which may not always be the case [13] . An analysis of the current drug target families reveals that transmembrane G-protein-coupled receptors (GPCRs) form the largest single class of targets. This large family of receptors has been successfully targeted using traditional chemical, biologic and structure-activity approaches. Not surprisingly, enzyme inhibitors comprise the broadest class of currently marketed small molecule agents [11, 14] . Enzymes, particularly those of pathogenic organisms, are well-recognized targets which afford a degree of specificity due to nonoverlap with host proteins; however, off-target effects remain a key issue for anti-infective enzyme inhibitors.
Whole-genome analysis of novel druggable targets revealed that kinase families are, in fact, more numerous than GPCRs, and are druggable because of common ATP-binding features of protein kinases [11] . A recent study [15] has exploited this, and used a sophisticated chemical and proteomic approach to capture endogenous protein kinases using immobilized, nonselective inhibitors (kinobeads). A clever use of mass spectrometry and analysis of drug-induced changes in phosphorylation states allowed profiling of specific patterns of inhibitors, levels of kinases and analysis of downstream effects. This approach allows for determination of specificity, affinity, and potential downstream effectors of therapeutic kinase inhibitors. Given the recent success of kinase inhibitors, particularly multitarget inhibitors, in neoplastic diseases (imatinib-Gleevec, dasatinib-Sprycel, sunitinib-Sutent), approaches that combine target and drug-based analysis are likely to yield additional NCEs [16] . However, numerous potentially new targets may not be amenable to analysis via protein family homology as have been protein kinase families. 
What Determines Druggability?
Relationships between current drugs and known targets have been used to empirically determine whether a novel, predicted protein from the genome is a potential target for drug action. Notable examples of this include GPCR families, protein kinases, and numerous enzymes. Structural and crystallographic methods are powerful technologies for translation of protein structural homology into specific characteristics of folds, turns and binding domains that may provide a druggable target [17, 18] ; however, membrane-bound proteins (e.g. GPCRs, ion channels) have proven difficult structures to solve using current biophysical methods. Protein fragment analysis may provide a partial solution to this issue, inasmuch as solvent-accessible domains of membrane-bound proteins are likely to be potential drug targets [19] . Conservation of binding site architecture is often a common feature between targets. In a recent comprehensive review [20] , a set of rules was proposed for druggable targets: (a) the protein is from a family that is related to a current known target; (b) sequence variation between the drug-binding domain and that of other related family members of human proteins should exist; (c) the protein has less than 6 similar proteins in the human family, minimizing off-target effects; (d) the target protein is involved in only one or two cellular signaling pathways, and (e) the protein is preferentially expressed in tissues specific to the disease state.
Several new approaches have been proposed to capitalize on enhanced methods for drug discovery. First, disease states are often more complex than single proteins and genes, often involving 30 or more genes, suggesting that a signaling pathway analysis may be more useful [21] . Second, both on-target and off-target drug networks need to be considered; this complex set of interactions can be used to predict disease-specific and side effect profiles. Moreover, such interaction patterns may be useful to predict effects of multiple drugs on a given patient [22] . Third, new and intriguing relationships between human disease phenotypes and genotypes have been established, leading to the concept of a human disease network linked by hub and spoke relationships [23] [24] [25] . This latter concept has led to a network showing previously unknown or unanticipated relationships between and among diseases. Each approach has specific merits, but an integrated link among these bioinformatic approaches may be most useful. An outline of these analyses is shown in figure 2 .
In the case of pathway analysis, specific gene derangements can be targeted to produce highly specific effects -targeting of the unusual fusion protein BCR-ABL kinase by imatinib in chronic myelogenous leukemia is perhaps the best example of targeting to a specific pathway [26] . The pathology of this subtype of chronic myelogenous leukemia is marked by the formation of this unusually active protein kinase fusion protein. Downstream phosphorylation events which ultimately drive cellular transformation can be turned off using imatinib with minimal side effects on other nontransformative protein kinase cascades [27] . However, not all pathways are as amenable to druggability as the BCR-ABL pathway -as a case in point, activating mutations of Ras are associated with numerous common malignancies. Because of the involvement of Ras in critical cellular pathways, targeting the constitutively activated molecule has proven difficult, since nonmutated Ras pathways are often inhibited [28] . Examination of downstream effectors, such as kinase-like suppressor of Ras (KSR-1), may be a useful target for certain malignancies involving Ras, such as pancreatic cancer, allowing some specificity related to the deranged pathway [29] . Thus, pathway analysis can be useful as a biologic system to explore the relationships between casual and correlative effects of the target, the disease and drug treatment.
The drug-target network approach has allowed the development of relationships between drug types categorized according to their Anatomical Therapeutic Chemical Classification and specific protein targets [22] . Interestingly, of all 1,178 FDA-approved agents, only 394 human proteins were targeted; extending the analysis to include over 3,000 experimental agents not yet approved increases the target number to over 1,000. The tight clustering of chemically dissimilar drugs around specific targets according to therapeutic classes underscores the relational base between known targets and disease applications, but does not fully inform about newer druggable targets in specific diseases. Of note, this approach also found that the average agent had 1.8 target interactions, suggesting a basis for off-target side effects as well.
Both pathway and drug network analyses offer powerful associational methods for determining drug-target interactions. Recent approaches have used gene networks to identify druggable targets, and subsequent refinements have led to the creation of the human 'diseasome' [12] . These maps have illuminated genetic links between seemingly unrelated diseases. As an example, angiotensinconverting enzyme has been linked to diabetes mellitus, renal tubular dysfunction, hypertension, and Alzheimer's disease. Proteins that link between disease states offer important targets for new drug development, and the construction of the bipartite disease network affords novel targets that link to currently untreated diseases of note [32] [33] [34] . For instance, relationships between cardiomyopathy and other peripheral muscular myopathies and muscular dystrophies suggest that agents effective against one disease may have applications in other myopathic changes.
What is now suggested is the ability to annotate, crossreference and cross-link potential new drug targets from these maps [30] . Starting with the disease network, novel, disease-linking gene products can be identified. From these maps, analysis using the drug network approach can reveal if the target is currently linked with an approved or experimental agent. If not, structural databases can be examined to determine whether the protein structure has been identified, or alternatively, whether fragment-based design can be used, based on known folds and motifs. Finally, computational and chemical screening can be refined to find leads ( fig. 3 ) .
Targeted Drugs to a Druggable Target
Oral drug administration is the preferential route of administration for chronic therapeutics. However, newer biologics, certain chemotherapeutics and insoluble pro- Schematic analysis of three bioinformatics-based drug discovery platforms. Each approach relies on relational databases that show patterns, strengths, and linkages between genes, diseases and drugs. a An outline of a signaling pathway analysis, in which any component could be a selective target for drug discovery. b Drug network analysis, depicting that a given target can have multiple divergent drugs that interact for therapeutic purposes; shown is an off-target gene which interacts with two of the targeted drugs, causing unwanted effects. c Schematic of a small portion of a disease-gene network. Linking genes may provide drug targets that apply to multiple, related conditions. Disease network model c teins and drugs with poor kinetic or distribution patterns must be administered parenterally. This has been part of the driving force to develop specific drug delivery systems that target and deliver drugs. Liposomal encapsulation, polyethylene glycol (PEG) modification, and monoclonal antibody or fusion proteins targeted to cell surface receptors are recognized tools in the repertoire of approved parenteral therapeutics [31] . Liposomal encapsulation of toxic chemotherapeutics reduces systemic toxicity of agents such as amphotericin B, doxorubicin, and cytosine arabinoside. However, liposomal targeting to specific cellular compartments has proven somewhat elusive, even though incorporation of targeting ligands into liposomes has been useful in several experimental systems.
The selectivity of fusion proteins (e.g. interleukin-2/ diphtheria toxin fusion; ONTAK) and various cell surface-specific monoclonal antibodies (e.g. Rituxan, Bexaar) has been exploited for successful chemotherapy [26] . The fundamental basis for targeting lies in the recognition of specific cell surface receptors which are often expressed on malignant cells. However, intracellular targets remain elusive to large molecule biologic therapies. This difficulty has raised hopes that nucleic acid therapeutics such as siRNA, miRNA and antisense-directed therapies might yield both specific and efficacious therapeutics [32] . Once again, systemic, cell-specific delivery of nucleic acid therapeutics in humans has proven to be difficult [33] .
Other approaches, such as PEG modification or drugprotein conjugation can favorably alter pharmacokinetics and free drug levels of biologics and chemotherapeutics. PEG-modified biologics are in wide clinical use, as are agents such as taxol conjugated to human albumin (Abraxane) in an attempt to lower toxicity of free drug and drug vehicle (Cremophor). These 'cloaking' methods primarily alter kinetics and distribution, but do not provide selective targeting. Nanomaterials of various compositions have been touted as both drug carriers and imaging agents [34] [35] [36] [37] . However, much more work will be needed in order to develop specific nanomaterial platforms as approved drug delivery vehicles. Ideally, new drug delivery systems should be mated with targeted novel therapies at the earliest stages of development. If new drug delivery systems can be devised that deliver specific payloads only to the desired site, and with a minimum of toxicity, a significant improvement in efficacy and safety will be obtained. However, the biologic barriers in humans will continue to present formidable challenges.
Conclusions
We live in Dickensian times, which is the best and the worst of times. Never before has so much information been generated concerning human disease targets, pro- tein structure and genomes, offering so much potential. Conversely, funding patterns, corporate restructuring, regulatory expectations, and cost-benefit issues have seemingly slowed the discovery and approval of new, potentially lifesaving agents with excellent efficacy to side effect profiles. It is important that the biomedical research community continue to exploit novel, integrative approaches for new drug and target discovery. Similarly, both regulatory agencies and for-profit industry must adapt to the changing patterns of discovery. The potential is looming for a renaissance of drug discovery and disease-specific therapies, with opportunities to target some of the most intractable diseases.
